NCT03221400: PEN-866 in Patients With Advanced Solid Malignancies

NCT03221400
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with leptomeningeal disease or symptomatic brain metastases that require treatment
https://ClinicalTrials.gov/show/NCT03221400

Comments are closed.

Up ↑